Weiyue Lu

Prof. Weiyue Lu


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2019 in ACS Nano
Verified
Journal Article
Closed access
ZCZhilan Chai
Zhilan Chai
DRDanni Ran
Danni Ran
LLLinwei Lu
Linwei Lu
CZChangyou Zhan
Changyou Zhan
HRHuitong Ruan
Huitong Ruan
WLWeiyue Lu
Weiyue Lu

26 July 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MLMin Liu
Min Liu
CLChong Li
Chong Li
MPMarzena Pazgier
Marzena Pazgier
CLChangqing Li
Changqing Li
YMYubin Mao
Yubin Mao
WLWuyuan Lu
Wuyuan Lu
The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53, conferring tumor development and survival. Antagonists targeting the p53-binding domains of MDM2 and MDMX kill tumor cells both in vitro and in vivo by reactivating the p53 pathway, promising a class of antitumor agents for cancer therapy. Aided by native chemical ligation and mirror image phage display, we recently identified a D-peptide inhibitor of the p53-MDM2 interaction termed D PMI-α (TNWYANLEKLLR) that competes with p53 for MDM2 binding at an affinity of 219 nM. Increased selection stringency resulted in a distinct D-peptide inhibitor termed D PMI-γ (DWWPLAFEALLR) that binds MDM2 at an affinity of 53 nM. Structural studies coupled with mutational analysis verified the mode of action of these D-peptides as MDM2-dependent p53 activators. Despite being resistant to proteolysis, both D PMI-α and D PMI-γ failed to actively traverse the cell membrane and, when conjugated to a cationic cell-penetrating peptide, were indiscriminately cytotoxic independently of p53 status. When encapsulated in liposomes decorated with an integrin-targeting cyclic-RGD peptide, however, D PMI-α exerted potent p53-dependent growth inhibitory activity against human glioblastoma in cell cultures and nude mouse xenograft models. Our findings validate D-peptide antagonists of MDM2 as a class of p53 activators for targeted molecular therapy of malignant neoplasms harboring WT p53 and elevated levels of MDM2.

1 October 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZCZhilan Chai
Zhilan Chai
XHXuefeng Hu
Xuefeng Hu
XWXiaoli Wei
Xiaoli Wei
CZChangyou Zhan
Changyou Zhan
LLLinwei Lu
Linwei Lu
WLWeiyue Lu
Weiyue Lu

1 June 2014 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XWXiaoli Wei
Xiaoli Wei
XCXishan Chen
Xishan Chen
MYMan Ying
Man Ying
WLWeiyue Lu
Weiyue Lu
Despite the application of aggressive surgery, radiotherapy and chemotherapy in clinics, brain tumors are still a difficult health challenge due to their fast development and poor prognosis. Brain tumor-targeted drug delivery systems, which increase drug accumulation in the tumor region and reduce toxicity in normal brain and peripheral tissue, are a promising new approach to brain tumor treatments. Since brain tumors exhibit many distinctive characteristics relative to tumors growing in peripheral tissues, potential targets based on continuously changing vascular characteristics and the microenvironment can be utilized to facilitate effective brain tumor-targeted drug delivery. In this review, we briefly describe the physiological characteristics of brain tumors, including blood-brain/brain tumor barriers, the tumor microenvironment, and tumor stem cells. We also review targeted delivery strategies and introduce a systematic targeted drug delivery strategy to overcome the challenges.

11 March 2019 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
HRHuitong Ruan
Huitong Ruan
QHQuanyin Hu
Quanyin Hu
DWDi Wen
Di Wen
QCQian Chen
Qian Chen
GCGuojun Chen
Guojun Chen
ZGZhen Gu
Zhen Gu

19 January 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
XWXiaoli Wei
Xiaoli Wei
CZChangyou Zhan
Changyou Zhan
QSQing Shen
Qing Shen
WFWei Fu
Wei Fu
CXCao Xie
Cao Xie
WLWeiyue Lu
Weiyue Lu